TITLE

Sanofi-Aventis to Buy BiPar Sciences

AUTHOR(S)
Marino, Jonathan
PUB. DATE
April 2009
SOURCE
Mergers & Acquisitions Report;4/20/2009, Vol. 22 Issue 16, p6
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the decision of French pharmaceutical company Sanofi-Aventis to purchase privately held biopharmaceutical company BiPar Sciences in a deal valued at 500 million dollars. BiPar Sciences was noted to be developing tumor-selective approaches including DNA repair techniques for cancer treatment. The deal is expected to be completed by the second quarter of 2009.
ACCESSION #
44127799

 

Related Articles

  • Prasco, Winthrop Ink Deals.  // Chain Drug Review;11/23/2009, Vol. 31 Issue 20, p54 

    The article reports on the move by Prasco Laboratories to work with Winthrop U.S., a business of Sanofi-Aventis US LLC , in providing sales support and distribution services for authorized generic versions of Allegra-D 12 Hour extended-release tablets and Drisdol capsules in the U.S. Prasco...

  • Covis Picks Up U.S. Rights to Pharma Products from Sanofi-Aventis. COLLINS, ALLISON // Mergers & Acquisitions Report;4/8/2013, Vol. 26 Issue 14, p1 

    The article informs that Covis Pharma Sarl has acquired the U.S. rights to five pharmaceutical products including Nilandron, Plaquenil, and Rilutek from Sanofi-Aventis US LLC. The products had 114.6 million U.S. dollars in sales for 2012. The rights to the assets outside of the U.S. will be...

  • Charles Hugh-Jones.  // Nature Reviews Drug Discovery;Dec2013, Vol. 12 Issue 12, p900 

    An interview with Charles Hugh-Jones, chief medical officer (CMO) at the pharmaceutical firm Sanofi, is presented. When asked about the reason to start the Project Data Sphere, he refers to increasing mortality rate and the project's clinical trial for cancer therapy. He discusses clinical data...

  • News in brief.  // Nature Reviews Drug Discovery;Mar2011, Vol. 10 Issue 3, p165 

    The article offers drug news briefs in the U.S. The Food and Drug Administration (FDA) panelists have called for higher hurdles for accelerated drugs approvals in oncology. According to a study, the public sector has contributed to the discovery of 153 drugs over the past 40 years. A number of...

  • Biotechnology News Round-up.  // PharmaWatch: Biotechnology;Oct2009, Vol. 8 Issue 10, p2 

    The article offers world news briefs related to the biotechnology industry. Gentech LLC has unveiled an encouraging data regarding the Ribbon 2 trial of Avastin in breast cancer. Sanofi-Aventis US LLC and Regeneron Phamaceuticals Inc. have decided to discontinue the Phase III trial which...

  • Barr challenges Eloxatin patent.  // PharmaWatch: Cancer;Feb2008, Vol. 7 Issue 2, p14 

    The article focuses on patent issues in connection with Eloxatin, a drug for colon cancer treatment. Barr Laboratories Inc. has initiated a challenge of the patents by Sanofi-Aventis U.S. LLC concerning its Eloxatin injectable, indicated for treatment of advanced carcinoma of the colon or...

  • Sanofi Seeks to Beef Up Cancer Line with BiPar. Young, Donna // BioWorld Today;4/16/2009, Vol. 20 Issue 72, p1 

    The article reports on the acquisition of cancer drugmaker BiPar Sciences Inc. by Sanofi-Aventis Group for a disclosed sum. The purchase price is said to be tied to the achievement of certain developmental milestones related to BiPars poly-ADP-ribose polymerase (PARP) inhibitor BSI-201. BiPar...

  • Sanofi-Aventis to Buy Firms in Brazil and U.S. Ramesh, Deepti // Chemical Week;4/20/2009, Vol. 171 Issue 11, p43 

    The article announces the agreement of Sanofi-Aventis to acquire Medley of Campinas, Brazil. Medley is the largest generics drugmaker and third-largest pharmaceutical company. Separately, Sanofi-Aventis finalized a deal to acquire BiPar Sciences, a privately held biopharmaceutical company....

  • Sanofi Seeks to Beef Up Cancer Line with BiPar.  // Bioworld Week;4/20/2009, Vol. 17 Issue 16, p4 

    The article reports on the acquisition of BiPar Sciences Inc., a cancer drugmaker, in a deal worth $500 million by Sanofi-Aventis Group in the U.S. The purchase value is linked to the accomplishment of certain developmental milestones relative to BiPar's poly-ADH-ribose polymerase (PARP)...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics